For this route, all the lipids and surfactants used in traditional dosage forms can be exploited. In addition, all compounds of GRAS status or accepted GRAS status can be employed as well as from the food industry [40]. Since the stomach acidic environment and high ionic strength favour the

particle aggregation, aqueous dispersions of lipid nanoparticles might not be suitable to be MGCD0103 mw administered as dosage form. In addition, the presence of food will also have a high impact on their performance [41]. The packing of SLN in a sachet for redispersion Inhibitors,research,lifescience,medical in water or juice prior to administration will allow an individual dosing by volume of the reconstituted SLN. For the production Inhibitors,research,lifescience,medical of tablets, the aqueous SLN dispersions can be used instead of a granulation fluid in the granulation process. Alternatively, SLN can be transferred to a powder (by spray-drying or lyophilization) and added to the tabletting powder mixture. In both cases, it is beneficial to have a higher

solid content to avoid the need of having to remove too much water. For cost reasons, spray drying might be the preferred method for transforming SLN dispersions into powders, with the previous addition of a protectant [42]. For the production of pellets, the SLN dispersion can be used as a wetting agent in the extrusion Inhibitors,research,lifescience,medical process. SLN powders can also be used for the filling of hard gelatine Inhibitors,research,lifescience,medical capsules. Alternatively, SLN can be produced directly in liquid PEG 600 and put into soft gelatine capsules. Advantages of the

use of SLN for oral and peroral administration are the possibility of drug protection from hydrolysis, as well as the possible increase of drug bioavailability. Prolonged plasma levels has also been postulated due to a controlled, optimized released [22] in combination with general adhesive properties of small particles [43]. The advantage of colloidal drug carriers described above is that they are generally linked to their size in the submicron range. Inhibitors,research,lifescience,medical Therefore, the preservation of particle size of colloidal carrier systems after peroral administration is a crucial point. The gastric environment (ionic strength, low pH) may destabilize the SLN and potentially lead to aggregation. However, it is possible to produce stable Oxalosuccinic acid SLN dispersions by optimizing the surfactant/mixture for each lipid in vitro [44]. The drug release from SLN in the GIT is also dependent on the lipase/colipase activity for the GIT digestion of the lipid matrix. The lipase/colipase complex leads to a degradation of food lipids as a prestep of the absorption. In vitro degradation assay based on pancreas lipase/colipase complex have been developed to obtain basic information about the degradation velocity of SLN as a function of lipid and surfactant used in the production process [45, 46].